Source - RNS
RNS Number : 6202K
Alliance Pharma PLC
23 September 2016

For immediate release

23 September 2016



("Alliance" or the "Company")


Exercise of Share Options


Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces that following the exercise of employee share options, application has been made by Alliance for a further 1,427,558 ordinary shares of 1p each in the Company ("Ordinary Shares") to be admitted to trading on AIM.


It is expected that these new Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares, will be admitted to trading on 26 September 2016.


After Admission, Alliance will have 471,093,833 Ordinary Shares in issue.



For further information:


Alliance Pharma plc

+ 44 (0) 1249 466966

John Dawson, Chief Executive Officer

Andrew Franklin, Chief Financial Officer

Sarah Robinson, Company Secretary



+ 44 (0) 20 7466 5000

Mark Court / Sophie Cowles / Jane Glover

Numis Securities Limited

+ 44 (0) 20 7260 1000

Nominated Adviser: Michael Meade / Freddie Barnfield

Corporate Broking: James Black / Toby Adcock


Notes to editors:


About Alliance Pharma

Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors.  Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

This information is provided by RNS
The company news service from the London Stock Exchange